Last update 23 Jan 2025

Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.

Private Company|
2020|
Jiangsu Sheng, China

Overview

Tags

Neoplasms
Endocrinology and Metabolic Disease
Digestive System Disorders
Fusion protein
CAR-T

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
CAR-T1
Fusion protein1
Top 5 TargetCount
MSLN(Mesothelin)1
CD276(CD276 antigen)1

Related

2
Drugs associated with Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
CHT-102
Target
MSLN
Mechanism
MSLN inhibitors
Active Org.
Tianjin Medical University Cancer Institute and HospitalTianjin Medical University Cancer Institute and Hospital [+1]
Originator Org.
Tianjin Medical University Cancer Institute and HospitalTianjin Medical University Cancer Institute and Hospital
Active Indication
Pancreatic Cancer [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
CN117843809
Patent Mining
Target
CD276
Mechanism-
Active Org.
Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
Originator Org.
Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
NCT06760364
/ Not yet recruitingPhase 1IIT
A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer
NCT06717022
/ RecruitingNot ApplicableIIT
A Clinical Study of CHT102, a Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) for Mesothelin(MSLN) Positive Advanced Solid Tumors: a Single-arm, Open-label, Dose Escalation and Expansion Clinical Study
NCT06730659
/ RecruitingPhase 1IIT
A Single-Arm, Open-Label, Phase I Study of CHT101 for CD70-Positive Relapsed/Refractory Solid Tumors
100 Clinical Results associated with Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
Login to view more data
100 Deals associated with Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
Login to view more data
100 Translational Medicine associated with Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
1
Phase 1 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
CHT-102
 ( MSLN )		Pancreatic Cancer
More
Phase 1
CN117843809
 ( CD276 )		Neoplasms
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free